Drugs / Autologous tumor infiltrating lymphocytes (TILs)
Autologous tumor infiltrating lymphocytes (TILs)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05366478 | May 2022 → May 2024 overdue | cervical carcinoma, melanoma, non-small cell lung carcinoma | Suzhou BlueHorse Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02414945 | May 2015 → Oct 2020 | malignant pleural mesothelioma | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous tumor infiltrating lymphocytes (TILs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366478 ↗ |
| Action | Deplete | “TILs are a type of white blood cells that recognizes tumor cells and enter them which causes the tumor cells to break down.” NCT02414945 ↗ |
| Modality | Cell therapy | “The investigational infusion product consists of autologous, in vitro-expanded tumor-infiltrating lymphocytes (TILs).” NCT02414945 ↗ |
| Route | Intravenous | “The cells are given intravenously over a 20-30 minute infusion.” NCT02414945 ↗ |